This document discusses anemia of chronic kidney disease (CKD), including its causes, prevalence, benefits of treatment, evaluation, and treatment with iron and erythropoietic stimulating agents (ESAs). It notes that anemia is common in CKD due to reduced kidney function and erythropoietin production. While untreated anemia can cause many symptoms, managing it with iron and ESAs can improve quality of life and reduce risks. The document provides guidelines on testing, supplementing iron, dosing ESAs, monitoring treatment response, and managing side effects in patients with CKD.